Treatments

You are here:Home/Treatments
Treatments2023-02-15T19:36:12+00:00

Treatments

Despite the fact that the prevalence of autism spectrum disorder (ASD) continues to rise, no effective medical treatments have become standard of care. As the pathophysiological abnormalities associated with ASD are studied, we hope that these revelations lead to associated treatments. Treatments targeting some of the abnormalities seen in ASD including neurotransmitter abnormalities, particularly imbalances in glutamate and acetylcholine, sleep onset disorder (with behavioral therapy and melatonin), and metabolic abnormalities in folate, cobalamin, tetrahydrobiopterin, carnitine, and redox pathways are being investigated. There is some evidence for treatments of epilepsy and seizures, mitochondrial and immune disorders, and gastrointestinal abnormalities, particularly imbalances in the enteric microbiome, but further clinical studies are needed in these areas to better define treatments specific to children with ASD. There are some promising areas of ASD research that could lead to novel treatments that could become standard of care in the future.

This page contains a selection of papers and other resources on this topic. You can also search this site and all types of content by creating a custom filter.

Autism Parents

Published Articles

Results are displayed in descending order beginning with most recent publications.

Synchrony 2022: Catalyzing Research and Treatments to Benefit Individuals with Neurodevelopmental Disorders including Autism Spectrum Disorders

Categories: Published Articles|Tags: , , , , , , , |

Nanda, H.; Frye, R.E. Synchrony 2022: Catalyzing Research and Treatments to Benefit Individuals with Neurodevelopmental Disorders including Autism Spectrum Disorders. J. Pers. Med. 2023, 13, 490. https://doi.org/10.3390/jpm13030490

Long COVID Syndrome Presenting as Neuropsychiatric Exacerbations in Autism Spectrum Disorder: Insights for Treatment

Categories: Published Articles|Tags: , , , , , , |

Jyonouchi, H.; Geng, L.; Rossignol, D.A.; Frye, R.E. Long COVID Syndrome Presenting as Neuropsychiatric Exacerbations in Autism Spectrum Disorder: Insights for Treatment. J. Pers. Med. 2022, 12, 1815. https://doi.org/10.3390/jpm12111815

Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis

Categories: Published Articles|Tags: , , , , , |

Rossignol DA, Frye RE. J Pers Med. 2021 Nov 3;11(11):1141. doi: 10.3390/jpm11111141. Erratum in: J Pers Med. 2022 Apr 29;12(5): PMID: 34834493; PMCID: PMC8622150.

Transdermal Electrical Neuromodulation for Anxiety and Sleep Problems in High-Functioning Autism Spectrum Disorder: Feasibility and Preliminary Findings

Categories: Published Articles|Tags: , , , , , |

Foldes ST, Jensen AR, Jacobson A, Vassall S, Foldes E, Guthery A, Brown D, Levine T, Tyler WJ, Frye RE. Transdermal Electrical Neuromodulation for Anxiety and Sleep Problems in High-Functioning Autism Spectrum Disorder: Feasibility and Preliminary Findings. J Pers Med. 2021 Dec 6;11(12):1307. doi: 10.3390/jpm11121307. PMID: 34945779; PMCID: PMC8704341.

Ratings of the Effectiveness of Nutraceuticals for Autism Spectrum Disorders: Results of a National Survey

Categories: Published Articles|Tags: , , , |

Adams, J.B.; Bhargava, A.; Coleman, D.M.; Frye, R.E.; Rossignol, D.A. Ratings of the Effectiveness of Nutraceuticals for Autism Spectrum Disorders: Results of a National Survey. J. Pers. Med. 2021, 11, 878. https://doi.org/10.3390/jpm11090878

Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder

Categories: Published Articles|Tags: , , , , |

Barone R, Bastin J, Djouadi F, Singh I, Karim MA, Ammanamanchi A, McCarty PJ, Delhey L, Shannon R, Casabona A, Rizzo R, Frye RE. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder. J Pers Med. 2021 Jun 4;11(6):510. doi: 10.3390/jpm11060510. PMID: 34199819; PMCID: PMC8229571.

Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

Categories: Published Articles|Tags: , , , , |

Zimmerman AW, Singh K, Connors SL, Liu H, Panjwani AA, Lee LC, Diggins E, Foley A, Melnyk S, Singh IN, James SJ, Frye RE, Fahey JW. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism. 2021 May 25;12(1):38. doi: 10.1186/s13229-021-00447-5. Erratum in: Mol Autism. 2021 Jun 16;12(1):44. PMID: 34034808; PMCID: PMC8146218.

Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms

Categories: Published Articles|Tags: , , , , , , |

Shimasaki C, Frye RE, Trifiletti R, Cooperstock M, Kaplan G, Melamed I, Greenberg R, Katz A, Fier E, Kem D, Traver D, Dempsey T, Latimer ME, Cross A, Dunn JP, Bentley R, Alvarez K, Reim S, Appleman J. Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms. J Neuroimmunol. 2020 Feb 15;339:577138. doi: 10.1016/j.jneuroim.2019.577138. Epub 2019 Dec 15. PMID: 31884258.

Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder

Categories: Published Articles|Tags: , , , , |

Barone R, Rizzo R, Tabbì G, Malaguarnera M, Frye RE, Bastin J. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder. Int J Mol Sci. 2019 Apr 16;20(8):1878. doi: 10.3390/ijms20081878. PMID: 30995737; PMCID: PMC6515064.

Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey

Categories: Published Articles|Tags: , , , , |

Coleman DM, Adams JB, Anderson AL, Frye RE. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):107-123. doi: 10.1089/cap.2018.0121. Epub 2019 Feb 6. PMID: 30724573; PMCID: PMC6442266.

Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism

Categories: Published Articles|Tags: , , , , , , |

Connery K, Tippett M, Delhey LM, Rose S, Slattery JC, Kahler SG, Hahn J, Kruger U, Cunningham MW, Shimasaki C, Frye RE. Transl Psychiatry. 2018 Aug 10;8(1):148. doi: 10.1038/s41398-018-0214-7. PMID: 30097568; PMCID: PMC6086890.

Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents

Categories: Published Articles|Tags: , , , |

Frye RE. Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. CNS Drugs. 2018 Aug;32(8):713-734. doi: 10.1007/s40263-018-0556-y. PMID: 30105528; PMCID: PMC6105175.

Comparison of Treatment for Metabolic Disorders Associated with Autism:Reanalysis of Three Clinical Trials

Categories: Published Articles|Tags: , , , |

Delhey LM, Tippett M, Rose S, Bennuri SC, Slattery JC, Melnyk S, James SJ, Frye RE. Comparison of Treatment for Metabolic Disorders Associated with Autism:Reanalysis of Three Clinical Trials. Front Neurosci. 2018 Feb 12;12:19. doi: 10.3389/fnins.2018.00019. PMID: 29483858; PMCID: PMC5816043.

Other Resources

A Personalized Medicine Approach to the Diagnosis and Management of Autism Spectrum Disorder

Categories: Books|Tags: , , , |

A Personalized Medicine Approach to the Diagnosis and Management of Autism Spectrum Disorder

Richard E Frye, Richard G Boles, Shannon Rose and Daniel Rossignol

This book is a reprint of the Special Issue A Personalized Medicine Approach to the Diagnosis and Management of Autism Spectrum Disorder that was published in JPM. This collection of articles provides the start of an overview of the current and future methods for applying a personalized medicine approach to the diagnosis, management, and treatment of autism.

Propranolol

Categories: Clinical Protocols, Treatments|Tags: , , , |

Propranolol

Propranolol is a blocker of beta-adrenergic receptor that acts both peripherally and centrally. Peripheral effects primarily target the autonomic nervous system where it affects primarily heart rate and blood pressure. Centrally targets include the wide spread norepinephrine circuits, including targets in the brainstem, cortex and most notably for ASD, amygdala. Propranolol has emerged as an interesting treatment for ASD that appears to improve social function

Title

Go to Top